Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Lung Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 157 articles: HTML format

Single Articles

July 2021
1. ROTHSCHILD SI, Zippelius A, Eboulet EI, Savic Prince S, et al
   SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
   J Clin Oncol. 2021 Jul 12:JCO2100276. doi: 10.1200/JCO.21.00276.
   PubMed     Abstract available
   
   
   June 2021
2. REMON J, Hendriks LEL, Besse B
   Paving the Way for Long-Term Survival in Non-Small-Cell Lung Cancer.
   J Clin Oncol. 2021 Jun 8:JCO2100760. doi: 10.1200/JCO.21.00760.
   PubMed    
   
   
   
3. PASSIGLIA F, Cinquini M, Bertolaccini L, Del Re M, et al
   Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis.
   J Clin Oncol. 2021 Jun 2:JCO2002574. doi: 10.1200/JCO.20.02574.
   PubMed     Abstract available
   
   
   April 2021
4. RECK M, Rodriguez-Abreu D, Robinson AG, Hui R, et al
   Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/= 50.
   J Clin Oncol. 2021 Apr 19:JCO2100174. doi: 10.1200/JCO.21.00174.
   PubMed     Abstract available
   
   
   March 2021
5. OWONIKOKO TK, Park K, Govindan R, Ready N, et al
   Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
   J Clin Oncol. 2021 Mar 8:JCO2002212. doi: 10.1200/JCO.20.02212.
   PubMed     Abstract available
   
   
   
6. DERKS JL, Speel EM, Dingemans AC
   Adjuvant Chemotherapy in Patients With Stage I-IIIA Large-Cell Neuroendocrine Carcinoma: Should a Different Approach Be Applied Than for Small-Cell Lung Cancer?
   J Clin Oncol. 2021 Mar 4:JCO2003598. doi: 10.1200/JCO.20.03598.
   PubMed    
   
   
   
7. DZIADZIUSZKO R, Krebs MG, De Braud F, Siena S, et al
   Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
   J Clin Oncol. 2021 Mar 1:JCO2003025. doi: 10.1200/JCO.20.03025.
   PubMed     Abstract available
   
   
   February 2021
8. HANNA NH, Robinson AG, Temin S, Baker S Jr, et al
   Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
   J Clin Oncol. 2021 Feb 16:JCO2003570. doi: 10.1200/JCO.20.03570.
   PubMed     Abstract available
   
   
   January 2021
9. BOYER M, Sendur MAN, Rodriguez-Abreu D, Park K, et al
   Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/= 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.
   J Clin Oncol. 2021 Jan 29:JCO2003579. doi: 10.1200/JCO.20.03579.
   PubMed     Abstract available
   
   
   
10. DALY ME, Ismaila N, Decker RH, Higgins K, et al
    Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline.
    J Clin Oncol. 2021 Jan 27:JCO2003364. doi: 10.1200/JCO.20.03364.
    PubMed     Abstract available
    
    
    
11. BORGHAEI H, Gettinger S, Vokes EE, Chow LQM, et al
    Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2021 Jan 15:JCO2001605. doi: 10.1200/JCO.20.01605.
    PubMed     Abstract available
    
    
    
12. LIU SV, Reck M, Mansfield AS, Mok T, et al
    Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
    J Clin Oncol. 2021 Jan 13:JCO2001055. doi: 10.1200/JCO.20.01055.
    PubMed     Abstract available
    
    
    December 2020
13. KENMOTSU H, Niho S, Tsuboi M, Wakabayashi M, et al
    Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206.
    J Clin Oncol. 2020;38:4292-4301.
    PubMed     Abstract available
    
    
    
14. BEKELMAN JE, Gupta A, Fishman E, Debono D, et al
    Association Between a National Insurer's Pay-for-Performance Program for Oncology and Changes in Prescribing of Evidence-Based Cancer Drugs and Spending.
    J Clin Oncol. 2020;38:4055-4063.
    PubMed     Abstract available
    
    
    November 2020
15. GARASSINO MC, Besse B, Torri V
    To Continue or Not to Continue? That Is the Question.
    J Clin Oncol. 2020;38:3830-3832.
    PubMed    
    
    
    
16. LAU YM, Mok TSK
    The More, The Better?
    J Clin Oncol. 2020;38:3581-3583.
    PubMed    
    
    
    
17. ANG E
    Four Women, One Evening.
    J Clin Oncol. 2020;38:3716-3718.
    PubMed    
    
    
    October 2020
18. BURNS TF, Borghaei H, Ramalingam SS, Mok TS, et al
    Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.
    J Clin Oncol. 2020 Oct 26:JCO2000744. doi: 10.1200/JCO.20.00744.
    PubMed    
    
    
    
19. OSAROGIAGBON RU
    Volume-Based Care Regionalization: Pitfalls and Challenges.
    J Clin Oncol. 2020;38:3465-3467.
    PubMed    
    
    
    
20. GOLDBERG SB, Redman MW, Lilenbaum R, Politi K, et al
    Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.
    J Clin Oncol. 2020 Oct 6:JCO2001149. doi: 10.1200/JCO.20.01149.
    PubMed     Abstract available
    
    
    September 2020
21. WATERHOUSE DM, Garon EB, Chandler J, McCleod M, et al
    Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
    J Clin Oncol. 2020 Sep 10:JCO2000131. doi: 10.1200/JCO.20.00131.
    PubMed     Abstract available
    
    
    August 2020
22. ZHOU C, Li X, Wang Q, Gao G, et al
    Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study.
    J Clin Oncol. 2020;38:2753-2761.
    PubMed     Abstract available
    
    
    
23. CAMIDGE DR, Kim HR, Ahn MJ, Yang JCH, et al
    Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
    J Clin Oncol. 2020 Aug 11:JCO2000505. doi: 10.1200/JCO.20.00505.
    PubMed     Abstract available
    
    
    
24. RUSTHOVEN CG, Camidge DR, Robin TP, Brown PD, et al
    Radiosurgery for Small-Cell Brain Metastases: Challenging the Last Bastion of Preferential Whole-Brain Radiotherapy Delivery.
    J Clin Oncol. 2020 Aug 10:JCO2001823. doi: 10.1200/JCO.20.01823.
    PubMed    
    
    
    
25. FARJAH F, Grau-Sepulveda MV, Gaissert H, Block M, et al
    Volume Pledge is Not Associated with Better Short-Term Outcomes After Lung Cancer Resection.
    J Clin Oncol. 2020 Aug 7:JCO2000329. doi: 10.1200/JCO.20.00329.
    PubMed     Abstract available
    
    
    May 2020
26. RUDIN CM, Awad MM, Navarro A, Gottfried M, et al
    Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
    J Clin Oncol. 2020 May 29:JCO2000793. doi: 10.1200/JCO.20.00793.
    PubMed     Abstract available
    
    
    
27. RECK M, Wehler T, Orlandi F, Nogami N, et al
    Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2020 May 27:JCO1903158. doi: 10.1200/JCO.19.03158.
    PubMed     Abstract available
    
    
    
28. KENMOTSU H, Yamamoto N, Yamanaka T, Yoshiya K, et al
    Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2020 May 14:JCO1902674. doi: 10.1200/JCO.19.02674.
    PubMed     Abstract available
    
    
    
29. LEVY EB, Fiel MI, Hamilton SR, Kleiner DE, et al
    State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials-A Multidisciplinary Approach.
    J Clin Oncol. 2020;38:1633-1640.
    PubMed     Abstract available
    
    
    March 2020
30. NORONHA V, Patil VM, Joshi A, Menon N, et al
    Reply to T. Tanaka et al and F. Liang.
    J Clin Oncol. 2020;38:844-846.
    PubMed    
    
    
    
31. LIANG F
    Contradiction Between Stated Statistical Analysis Method and Displayed Survival Curves.
    J Clin Oncol. 2020;38:844.
    PubMed    
    
    
    
32. GADGEEL S, Rodriguez-Abreu D, Speranza G, Esteban E, et al
    Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2020 Mar 9:JCO1903136. doi: 10.1200/JCO.19.03136.
    PubMed     Abstract available
    
    
    
33. RAMALINGAM SS, Dahlberg SE
    Reply to N. Hanna et al and L. Xie et al.
    J Clin Oncol. 2020;38:771-772.
    PubMed    
    
    
    
34. HANNA N, Jalal S
    The Case for Maintenance Pemetrexed Plus Bevacizumab.
    J Clin Oncol. 2020;38:770-771.
    PubMed    
    
    
    February 2020
35. HERBST RS, Garon EB, Kim DW, Cho BC, et al
    Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1Positive, Advanced NonSmall-Cell Lung Cancer in the KEYNOTE-010 Study.
    J Clin Oncol. 2020 Feb 20:JCO1902446. doi: 10.1200/JCO.19.02446.
    PubMed     Abstract available
    
    
    January 2020
36. HANNA NH, Schneider BJ, Temin S, Baker S Jr, et al
    Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
    J Clin Oncol. 2020 Jan 28:JCO1903022. doi: 10.1200/JCO.19.03022.
    PubMed     Abstract available
    
    
    
37. WU YL, Zhong WZ, Yan HH
    Reply to A. Tateishi et al.
    J Clin Oncol. 2020;38:286-287.
    PubMed    
    
    
    
38. TATEISHI A, Ishiki H, Kubo E, Satomi E, et al
    EMERGING-CTONG 1103: For Achieving High-Quality Evidence in a Randomized Phase II Trial.
    J Clin Oncol. 2020;38:285-286.
    PubMed    
    
    
    
39. XIE L, Fan X, Qian B
    Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: More Questions Than Answers.
    J Clin Oncol. 2020 Jan 2:JCO1902356. doi: 10.1200/JCO.19.02356.
    PubMed    
    
    
    
40. TANAKA T, Ishiki H, Kubo E, Yokota S, et al
    Is Gefitinib Combined With Platinum-Doublet Chemotherapy a Counterpart to Osimertinib Monotherapy in Advanced EGFR-Mutated Non-Small-Cell Lung Cancer in the First-Line Setting?
    J Clin Oncol. 2020 Jan 2:JCO1902509. doi: 10.1200/JCO.19.02509.
    PubMed    
    
    
    December 2019
41. SETO T, Azuma K, Yamanaka T, Sugawara S, et al
    Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L).
    J Clin Oncol. 2019 Dec 27:JCO1901494. doi: 10.1200/JCO.19.01494.
    PubMed     Abstract available
    
    
    
42. BRADLEY JD, Hu C, Komaki RR, Masters GA, et al
    Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Dec 16:JCO1901162. doi: 10.1200/JCO.19.01162.
    PubMed     Abstract available
    
    
    
43. PILLAI RN, Fennell DA, Kovcin V, Ciuleanu TE, et al
    Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2).
    J Clin Oncol. 2019 Dec 12:JCO1900816. doi: 10.1200/JCO.19.00816.
    PubMed     Abstract available
    
    
    
44. SCHNEIDER BJ, Ismaila N, Aerts J, Chiles C, et al
    Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline.
    J Clin Oncol. 2019 Dec 12:JCO1902748. doi: 10.1200/JCO.19.02748.
    PubMed     Abstract available
    
    
    
45. CHO JH, Lim SH, An HJ, Kim KH, et al
    Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
    J Clin Oncol. 2019 Dec 11:JCO1900931. doi: 10.1200/JCO.19.00931.
    PubMed     Abstract available
    
    
    
46. YANG JCH, Kim SW, Kim DW, Lee JS, et al
    Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.
    J Clin Oncol. 2019 Dec 6:JCO1900457. doi: 10.1200/JCO.19.00457.
    PubMed     Abstract available
    
    
    November 2019
47. ROTOW JK, Janne PA
    What's Old Is New Again: Revisiting Up-Front Chemotherapy in EGFR-Mutated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Nov 27:JCO1902724. doi: 10.1200/JCO.19.02724.
    PubMed    
    
    
    
48. MAZIERES J, Kowalski D, Luft A, Vicente D, et al
    Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Nov 21:JCO1901348. doi: 10.1200/JCO.19.01348.
    PubMed     Abstract available
    
    
    
49. HOSOMI Y, Morita S, Sugawara S, Kato T, et al
    Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
    J Clin Oncol. 2019 Nov 4:JCO1901488. doi: 10.1200/JCO.19.01488.
    PubMed     Abstract available
    
    
    September 2019
50. DIRKSEN U, Brennan B, Le Deley MC, Cozic N, et al
    High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.
    J Clin Oncol. 2019 Sep 25:JCO1900915. doi: 10.1200/JCO.19.00915.
    PubMed     Abstract available
    
    
    August 2019
51. SIO TT, Mohindra P, Yu NY, Ashman JB, et al
    The Search for Optimal Stereotactic Body Radiotherapy Dose in Inoperable, Centrally Located Non-Small-Cell Lung Cancer Continues.
    J Clin Oncol. 2019 Aug 29:JCO1901330. doi: 10.1200/JCO.19.01330.
    PubMed    
    
    
    
52. NORONHA V, Patil VM, Joshi A, Menon N, et al
    Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.
    J Clin Oncol. 2019 Aug 14:JCO1901154. doi: 10.1200/JCO.19.01154.
    PubMed     Abstract available
    
    
    July 2019
53. RAMALINGAM SS, Dahlberg SE, Belani CP, Saltzman JN, et al
    Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508.
    J Clin Oncol. 2019 Jul 30:JCO1901006. doi: 10.1200/JCO.19.01006.
    PubMed     Abstract available
    
    
    June 2019
54. RICCIUTI B, Dahlberg SE, Adeni A, Sholl LM, et al
    Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications.
    J Clin Oncol. 2019 Jun 17:JCO1900189. doi: 10.1200/JCO.19.00189.
    PubMed     Abstract available
    
    
    
55. ZHONG WZ, Chen KN, Chen C, Gu CD, et al
    Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.
    J Clin Oncol. 2019 Jun 13:JCO1900075. doi: 10.1200/JCO.19.00075.
    PubMed     Abstract available
    
    
    
56. GARON EB, Hellmann MD, Rizvi NA, Carcereny E, et al
    Five-Year Overall Survival for Patients With Advanced NonSmall-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.
    J Clin Oncol. 2019 Jun 2:JCO1900934. doi: 10.1200/JCO.19.00934.
    PubMed     Abstract available
    
    
    
57. RANGACHARI D, Costa DB
    From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer.
    J Clin Oncol. 2019 Jun 2:JCO1901207. doi: 10.1200/JCO.19.01207.
    PubMed    
    
    
    May 2019
58. GOMEZ DR, Tang C, Zhang J, Blumenschein GR Jr, et al
    Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.
    J Clin Oncol. 2019 May 8:JCO1900201. doi: 10.1200/JCO.19.00201.
    PubMed     Abstract available
    
    
    April 2019
59. PASSARO A, Spitaleri G, Gyawali B, de Marinis F, et al
    Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence.
    J Clin Oncol. 2019 Apr 17:JCO1802118. doi: 10.1200/JCO.18.02118.
    PubMed    
    
    
    
60. BEZJAK A, Paulus R, Gaspar LE, Timmerman RD, et al
    Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.
    J Clin Oncol. 2019 Apr 3:JCO1800622. doi: 10.1200/JCO.18.00622.
    PubMed     Abstract available
    
    
    March 2019
61. SHAW AT, Solomon BJ, Besse B, Bauer TM, et al
    ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Mar 20:JCO1802236. doi: 10.1200/JCO.18.02236.
    PubMed     Abstract available
    
    
    February 2019
62. CAMIDGE DR, Davies KD
    MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Feb 27:JCO1900033. doi: 10.1200/JCO.19.00033.
    PubMed    
    
    
    
63. READY N, Hellmann MD, Awad MM, Otterson GA, et al
    First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
    J Clin Oncol. 2019 Feb 20:JCO1801042. doi: 10.1200/JCO.18.01042.
    PubMed     Abstract available
    
    
    January 2019
64. LAI GGY, Lim TH, Lim J, Liew PJR, et al
    Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Jan 24:JCO1800177. doi: 10.1200/JCO.18.00177.
    PubMed     Abstract available
    
    
    
65. LISBERG A, Garon EB
    Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?
    J Clin Oncol. 2019 Jan 24:JCO1801534. doi: 10.1200/JCO.18.01534.
    PubMed    
    
    
    
66. PIETANZA MC, Diao L, Wang J, Byers LA, et al
    Reply to F. Liang.
    J Clin Oncol. 2019;37:259.
    PubMed    
    
    
    
67. RECK M, Rodriguez-Abreu D, Robinson AG, Hui R, et al
    Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
    J Clin Oncol. 2019 Jan 8:JCO1800149. doi: 10.1200/JCO.18.00149.
    PubMed     Abstract available
    
    
    December 2018
68. MARCOUX N, Gettinger SN, O'Kane G, Arbour KC, et al
    EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
    J Clin Oncol. 2018 Dec 14:JCO1801585. doi: 10.1200/JCO.18.01585.
    PubMed     Abstract available
    
    
    
69. OWONIKOKO TK, Dahlberg SE, Sica GL, Wagner LI, et al
    Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study.
    J Clin Oncol. 2018 Dec 5:JCO1800264. doi: 10.1200/JCO.18.00264.
    PubMed     Abstract available
    
    
    November 2018
70. LIANG F
    Is SLFN11 a Promising Predictive Biomarker of Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Small-Cell Lung Cancer? Not Yet!
    J Clin Oncol. 2018 Nov 29:JCO1800993. doi: 10.1200/JCO.18.00993.
    PubMed    
    
    
    
71. PENNELL NA, Neal JW, Chaft JE, Azzoli CG, et al
    SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Nov 16:JCO1800131. doi: 10.1200/JCO.18.00131.
    PubMed     Abstract available
    
    
    October 2018
72. ZENG H, Yuan S, Yu J
    Prophylactic Cranial Irradiation in Non-Small-Cell Lung Cancer: Hope or Hype?
    J Clin Oncol. 2018 Oct 22:JCO1800617. doi: 10.1200/JCO.18.00617.
    PubMed    
    
    
    
73. ADDEO A, Caparrotti F, Picardi C, Dietrich PY, et al
    Prophylactic Cranial Irradiation in Stage III Non-Small-Cell Lung Cancer: Overall Survival Should Not Necessarily Be the Final End Point.
    J Clin Oncol. 2018 Oct 22:JCO1800461. doi: 10.1200/JCO.18.00461.
    PubMed    
    
    
    
74. RUSTHOVEN CG
    Prophylactic Cranial Irradiation in Non-Small-Cell Lung Cancer: The Costs Outweigh the Benefits.
    J Clin Oncol. 2018 Oct 22:JCO1800732. doi: 10.1200/JCO.18.00732.
    PubMed    
    
    
    September 2018
75. ZENG L, Yang N, Zhang Y
    Should Crizotinib Take It All in ROS1-Positive Non-Small-Cell Lung Cancer?
    J Clin Oncol. 2018 Sep 13:JCO1800119. doi: 10.1200/JCO.18.00119.
    PubMed    
    
    
    August 2018
76. WU YL, Zhang L, Kim DW, Liu X, et al
    Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Endothelial Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Aug 29:JCO2018777326. doi: 10.1200/JCO.2018.77.7326.
    PubMed     Abstract available
    
    
    
77. REUNGWETWATTANA T, Nakagawa K, Cho BC, Cobo M, et al
    CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Aug 28:JCO2018783118. doi: 10.1200/JCO.2018.78.3118.
    PubMed     Abstract available
    
    
    
78. WANG YN, Yao S, Wang CL, Li MS, et al
    Clinical Significance of 4L Lymph Node Dissection in Left Lung Cancer.
    J Clin Oncol. 2018 Aug 27:JCO2018787101. doi: 10.1200/JCO.2018.78.7101.
    PubMed     Abstract available
    
    
    
79. DE RUYSSCHER DKM, Decaluwe H
    4L Lymph Node Involvement in Left-Sided Lung Cancer: Unique or Not?
    J Clin Oncol. 2018 Aug 27:JCO2018793299. doi: 10.1200/JCO.2018.79.3299.
    PubMed    
    
    
    
80. ARBOUR KC, Mezquita L, Long N, Rizvi H, et al
    Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Aug 20:JCO2018790006. doi: 10.1200/JCO.2018.79.0006.
    PubMed     Abstract available
    
    
    
81. DEVARAKONDA S, Rotolo F, Tsao MS, Lanc I, et al
    Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Aug 14:JCO2018781963. doi: 10.1200/JCO.2018.78.1963.
    PubMed     Abstract available
    
    
    July 2018
82. WU YL, Ahn MJ, Garassino MC, Han JY, et al
    CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
    J Clin Oncol. 2018 Jul 30:JCO2018779363. doi: 10.1200/JCO.2018.77.9363.
    PubMed     Abstract available
    
    
    
83. GRIDELLI C, Morabito A, Cavanna L, Luciani A, et al
    Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials.
    J Clin Oncol. 2018 Jul 20:JCO2017768390. doi: 10.1200/JCO.2017.76.8390.
    PubMed     Abstract available
    
    
    June 2018
84. DONINGTON JS
    Thoracotomy for Stage I Lung Cancer Resections: A Procedure Past Its Time.
    J Clin Oncol. 2018 Jun 26:JCO2018793042. doi: 10.1200/JCO.2018.79.3042.
    PubMed    
    
    
    
85. ZWEIG JR, Neal JW
    Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer.
    J Clin Oncol. 2018 Jun 25:JCO2018788554. doi: 10.1200/JCO.2018.78.8554.
    PubMed    
    
    
    
86. PIETANZA MC, Waqar SN, Krug LM, Dowlati A, et al
    Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Jun 15:JCO2018777672. doi: 10.1200/JCO.2018.77.7672.
    PubMed     Abstract available
    
    
    
87. MOK TS, Cheng Y, Zhou X, Lee KH, et al
    Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
    J Clin Oncol. 2018 Jun 4:JCO2018787994. doi: 10.1200/JCO.2018.78.7994.
    PubMed     Abstract available
    
    
    
88. PIOTROWSKA Z, Gainor JF
    ARCHER 1050: Hitting an Important Mark in EGFR-Mutant Lung Cancer?
    J Clin Oncol. 2018 Jun 4:JCO2018793059. doi: 10.1200/JCO.2018.79.3059.
    PubMed    
    
    
    May 2018
89. BOFFA DJ, Kosinski AS, Furnary AP, Kim S, et al
    Minimally Invasive Lung Cancer Surgery Performed by Thoracic Surgeons as Effective as Thoracotomy.
    J Clin Oncol. 2018 May 23:JCO2018778977. doi: 10.1200/JCO.2018.77.8977.
    PubMed     Abstract available
    
    
    
90. DE RUYSSCHER D, Dingemans AC, Praag J, Belderbos J, et al
    Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study.
    J Clin Oncol. 2018 May 22:JCO2017775817. doi: 10.1200/JCO.2017.77.5817.
    PubMed     Abstract available
    
    
    
91. CAMIDGE DR, Kim DW, Tiseo M, Langer CJ, et al
    Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
    J Clin Oncol. 2018 May 16:JCO2017775841. doi: 10.1200/JCO.2017.77.5841.
    PubMed     Abstract available
    
    
    
92. SOLOMON BJ, Kim DW, Wu YL, Nakagawa K, et al
    Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 May 16:JCO2017774794. doi: 10.1200/JCO.2017.77.4794.
    PubMed     Abstract available
    
    
    
93. COPUR MS, Crockett D, Gauchan D, Ramaekers R, et al
    Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Targeted Therapy.
    J Clin Oncol. 2018 May 15:JCO2018788240. doi: 10.1200/JCO.2018.78.8240.
    PubMed    
    
    
    
94. LEONARDI GC, Gainor JF, Altan M, Kravets S, et al
    Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.
    J Clin Oncol. 2018 May 10:JCO2017770305. doi: 10.1200/JCO.2017.77.0305.
    PubMed     Abstract available
    
    
    
95. RENGAN R, Redman M, Zeng J
    Challenge of Proving the Value of Proton Therapy in an Unselected Patient Population in the Era of Precision Oncology: The Fallacy of a One-Size-Fits-All Strategy in Radiotherapy for Lung Cancer.
    J Clin Oncol. 2018 May 10:JCO2018783803. doi: 10.1200/JCO.2018.78.3803.
    PubMed    
    
    
    
96. LEE CK, Novello S, Ryden A, Mann H, et al
    Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial.
    J Clin Oncol. 2018 May 7:JCO2017772293. doi: 10.1200/JCO.2017.77.2293.
    PubMed     Abstract available
    
    
    April 2018
97. REINMUTH N, Reck M
    Breaking the Glass Ceiling of Overall Survival in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Apr 30:JCO2018782102. doi: 10.1200/JCO.2018.78.2102.
    PubMed    
    
    
    March 2018
98. WU YL, Yang JC, Kim DW, Lu S, et al
    Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Mar 29:JCO2017755587. doi: 10.1200/JCO.2017.75.5587.
    PubMed     Abstract available
    
    
    
99. GETTINGER S, Horn L, Jackman D, Spigel D, et al
    Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.
    J Clin Oncol. 2018 Mar 23:JCO2017770412. doi: 10.1200/JCO.2017.77.0412.
    PubMed     Abstract available
    
    
    
100. JAGSI R, Griffith KA, Bellon JR, Woodward WA, et al
     Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.
     J Clin Oncol. 2018 Mar 20:JCO2017772665. doi: 10.1200/JCO.2017.77.2665.
     PubMed     Abstract available
     
     
     
101. LU S, Chang J, Liu X, Shi J, et al
     Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous NonSmall-Cell Lung Cancer.
     J Clin Oncol. 2018 Mar 12:JCO2017767145. doi: 10.1200/JCO.2017.76.7145.
     PubMed     Abstract available
     
     
     February 2018
102. KALEMKERIAN GP, Narula N, Kennedy EB, Biermann WA, et al
     Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for
     J Clin Oncol. 2018 Feb 5:JCO2017767293. doi: 10.1200/JCO.2017.76.7293.
     PubMed     Abstract available
     
     
     January 2018
103. LIN JJ, Zhu VW, Yoda S, Yeap BY, et al
     Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
     J Clin Oncol. 2018 Jan 26:JCO2017762294. doi: 10.1200/JCO.2017.76.2294.
     PubMed     Abstract available
     
     
     
104. STOKES WA, Bronsert MR, Meguid RA, Blum MG, et al
     Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2018 Jan 18:JCO2017756536. doi: 10.1200/JCO.2017.75.6536.
     PubMed     Abstract available
     
     
     
105. RIZVI H, Sanchez-Vega F, La K, Chatila W, et al
     Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
     J Clin Oncol. 2018 Jan 16:JCO2017753384. doi: 10.1200/JCO.2017.75.3384.
     PubMed     Abstract available
     
     
     
106. LIAO Z, Lee JJ, Komaki R, Gomez DR, et al
     Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2018 Jan 2:JCO2017740720. doi: 10.1200/JCO.2017.74.0720.
     PubMed     Abstract available
     
     
     December 2017
107. OBEID R, Pietrzik K
     Smoking, B Vitamins, and Lung Cancer: The Chicken or the Egg Causality Dilemma.
     J Clin Oncol. 2017 Dec 28:JCO2017759472. doi: 10.1200/JCO.2017.75.9472.
     PubMed    
     
     
     
108. FRANCIS S, Orton A, Stoddard G, Tao R, et al
     Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally Advanced or Incompletely Resected Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2017 Dec 13:JCO2017744771. doi: 10.1200/JCO.2017.74.4771.
     PubMed     Abstract available
     
     
     November 2017
109. VAN HOEF MEHM
     Additional Recommendations for ALK Gene-Rearranged Non-Small-Cell Lung Cancer to the Recently Updated American Society of Clinical Oncology Guideline for Stage IV Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2017 Nov 22:JCO2017758367. doi: 10.1200/JCO.2017.75.8367.
     PubMed    
     
     
     
110. SCHNEIDER BJ, Daly ME, Kennedy EB, Antonoff MB, et al
     Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline.
     J Clin Oncol. 2017 Nov 6:JCO2017749671. doi: 10.1200/JCO.2017.74.9671.
     PubMed     Abstract available
     
     
     
111. GROSSO F, Steele N, Novello S, Nowak AK, et al
     Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
     J Clin Oncol. 2017;35:3591-3600.
     PubMed     Abstract available
     
     
     
112. WHITNEY RL, Bell JF, Tancredi DJ, Romano PS, et al
     Hospitalization Rates and Predictors of Rehospitalization Among Individuals With Advanced Cancer in the Year After Diagnosis.
     J Clin Oncol. 2017;35:3610-3617.
     PubMed     Abstract available
     
     
     October 2017
113. BUTTNER R, Gosney JR, Skov BG, Adam J, et al
     Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2017 Oct 20:JCO2017747642. doi: 10.1200/JCO.2017.74.7642.
     PubMed     Abstract available
     
     
     
114. HORN L, Spigel DR, Vokes EE, Holgado E, et al
     Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
     J Clin Oncol. 2017 Oct 12:JCO2017743062. doi: 10.1200/JCO.2017.74.3062.
     PubMed     Abstract available
     
     
     
115. SMIT EF, Haanen JBAG
     Pembrolizumab in Small-Cell Lung Cancer: In Search of the Best Biomarker.
     J Clin Oncol. 2017 Oct 10:JCO2017745141. doi: 10.1200/JCO.2017.74.5141.
     PubMed    
     
     
     
116. NELSON DB, Rice DC, Niu J, Atay S, et al
     Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.
     J Clin Oncol. 2017;35:3354-3362.
     PubMed     Abstract available
     
     
     
117. MOK TSK, Kim SW, Wu YL, Nakagawa K, et al
     Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.
     J Clin Oncol. 2017 Oct 2:JCO2017739250. doi: 10.1200/JCO.2017.73.9250.
     PubMed     Abstract available
     
     
     September 2017
118. KUBOTA K, Yoshioka H, Oshita F, Hida T, et al
     Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2017 Sep 13:JCO2017727297. doi: 10.1200/JCO.2017.72.7297.
     PubMed     Abstract available
     
     
     
119. O'NEILL AF, Towbin AJ, Krailo MD, Xia C, et al
     Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group.
     J Clin Oncol. 2017 Sep 11:JCO2017735654. doi: 10.1200/JCO.2017.73.5654.
     PubMed     Abstract available
     
     
     
120. LEE JK, Lee J, Kim S, Kim S, et al
     Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.
     J Clin Oncol. 2017;35:3065-3074.
     PubMed     Abstract available
     
     
     
121. KRIS MG, Gaspar LE, Chaft JE, Kennedy EB, et al
     Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.
     J Clin Oncol. 2017;35:2960-2974.
     PubMed     Abstract available
     
     
     August 2017
122. GOVINDAN R, Szczesna A, Ahn MJ, Schneider CP, et al
     Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2017 Aug 30:JCO2016717629. doi: 10.1200/JCO.2016.71.7629.
     PubMed     Abstract available
     
     
     
123. RAMALINGAM SS, Yang JC, Lee CK, Kurata T, et al
     Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2017 Aug 25:JCO2017747576. doi: 10.1200/JCO.2017.74.7576.
     PubMed     Abstract available
     
     
     
124. BRASKY TM, White E, Chen CL
     Long-Term, Supplemental, One-Carbon Metabolism-Related Vitamin B Use in Relation to Lung Cancer Risk in the Vitamins and Lifestyle (VITAL) Cohort.
     J Clin Oncol. 2017 Aug 22:JCO2017727735. doi: 10.1200/JCO.2017.72.7735.
     PubMed     Abstract available
     
     
     
125. OTT PA, Elez E, Hiret S, Kim DW, et al
     Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.
     J Clin Oncol. 2017 Aug 16:JCO2017725069. doi: 10.1200/JCO.2017.72.5069.
     PubMed     Abstract available
     
     
     
126. HANNA N, Johnson D, Temin S, Baker S Jr, et al
     Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
     J Clin Oncol. 2017 Aug 14:JCO2017746065. doi: 10.1200/JCO.2017.74.6065.
     PubMed     Abstract available
     
     
     
127. IKOMA N, You YN, Bednarski BK, Rodriguez-Bigas MA, et al
     Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer.
     J Clin Oncol. 2017;35:2631-2638.
     PubMed     Abstract available
     
     
     
128. NIPP RD, Greer JA, El-Jawahri A, Moran SM, et al
     Coping and Prognostic Awareness in Patients With Advanced Cancer.
     J Clin Oncol. 2017;35:2551-2557.
     PubMed     Abstract available
     
     
     July 2017
129. YANG JJ, Yu D, Takata Y, Smith-Warner SA, et al
     Dietary Fat Intake and Lung Cancer Risk: A Pooled Analysis.
     J Clin Oncol. 2017 Jul 25:JCO2017733329. doi: 10.1200/JCO.2017.73.3329.
     PubMed     Abstract available
     
     
     
130. TAN DSW
     Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade.
     J Clin Oncol. 2017 Jul 17:JCO2017736215. doi: 10.1200/JCO.2017.73.6215.
     PubMed    
     
     
     
131. FARAGO AF, Piotrowska Z, Sequist LV
     Unlocking the Mystery of Small-Cell Lung Cancer Transformations in EGFR Mutant Adenocarcinoma.
     J Clin Oncol. 2017 Jul 10:JCO2017735696. doi: 10.1200/JCO.2017.73.5696.
     PubMed    
     
     
     
132. BENDZSAK AM, Baxter NN, Darling GE, Austin PC, et al
     Regionalization and Outcomes of Lung Cancer Surgery in Ontario, Canada.
     J Clin Oncol. 2017 Jul 6:JCO2016698076. doi: 10.1200/JCO.2016.69.8076.
     PubMed     Abstract available
     
     
     June 2017
133. HAN SS, Rivera GA, Tammemagi MC, Plevritis SK, et al
     Risk Stratification for Second Primary Lung Cancer.
     J Clin Oncol. 2017 Jun 23:JCO2017724203. doi: 10.1200/JCO.2017.72.4203.
     PubMed     Abstract available
     
     
     
134. BURRIS HA, Infante JR, Ansell SM, Nemunaitis JJ, et al
     Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
     J Clin Oncol. 2017;35:2028-2036.
     PubMed     Abstract available
     
     
     
135. PETERS S, Gettinger S, Johnson ML, Janne PA, et al
     Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
     J Clin Oncol. 2017 Jun 13:JCO2016719476. doi: 10.1200/JCO.2016.71.9476.
     PubMed     Abstract available
     
     
     
136. JALAL SI, Lavin P, Lo G, Lebel F, et al
     Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE).
     J Clin Oncol. 2017 Jun 12:JCO2016717454. doi: 10.1200/JCO.2016.71.7454.
     PubMed     Abstract available
     
     
     May 2017
137. HEIST RS, Guarino MJ, Masters G, Purcell WT, et al
     Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
     J Clin Oncol. 2017 May 26:JCO2016721894. doi: 10.1200/JCO.2016.72.1894.
     PubMed     Abstract available
     
     
     
138. EBERHARDT WEE
     How Should We Choose the Best Therapy for Elderly Patients With Stage III Non-Small-Cell Lung Cancer?
     J Clin Oncol. 2017 May 24:JCO2017729053. doi: 10.1200/JCO.2017.72.9053.
     PubMed    
     
     
     
139. LIM SM, Kim HR, Lee JS, Lee KH, et al
     Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
     J Clin Oncol. 2017 May 18:JCO2016713701. doi: 10.1200/JCO.2016.71.3701.
     PubMed     Abstract available
     
     
     
140. OU SI
     Further Advances in the Management of Anaplastic Lymphoma Kinase-Mutated Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2017 May 11:JCO2017731323. doi: 10.1200/JCO.2017.73.1323.
     PubMed    
     
     
     
141. STINCHCOMBE TE, Zhang Y, Vokes EE, Schiller JH, et al
     Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.
     J Clin Oncol. 2017 May 11:JCO2016714758. doi: 10.1200/JCO.2016.71.4758.
     PubMed     Abstract available
     
     
     
142. EDELMAN MJ, Wang X, Hodgson L, Cheney RT, et al
     Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
     J Clin Oncol. 2017 May 10:JCO2016713743. doi: 10.1200/JCO.2016.71.3743.
     PubMed     Abstract available
     
     
     
143. POPAT S
     Do Statins Improve Survival in Small-Cell Lung Cancer?
     J Clin Oncol. 2017;35:1497-1498.
     PubMed    
     
     
     
144. CHALMERS A, Akerley W
     Retrospective, Multi-Institutional Analysis of Sequential Treatment of Brain Metastases in Treatment-Naive, Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer Should Not Define the Standard of Practice.
     J Clin Oncol. 2017 May 8:JCO2017727255. doi: 10.1200/JCO.2017.72.7255.
     PubMed    
     
     
     
145. KIM DW, Tiseo M, Ahn MJ, Reckamp KL, et al
     Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
     J Clin Oncol. 2017 May 5:JCO2016715904. doi: 10.1200/JCO.2016.71.5904.
     PubMed     Abstract available
     
     
     
146. GAUTSCHI O, Milia J, Filleron T, Wolf J, et al
     Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
     J Clin Oncol. 2017;35:1403-1410.
     PubMed     Abstract available
     
     
     April 2017
147. SHEPHERD FA, Lacas B, Le Teuff G, Hainaut P, et al
     Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
     J Clin Oncol. 2017 Apr 28:JCO2016712893. doi: 10.1200/JCO.2016.71.2893.
     PubMed     Abstract available
     
     
     
148. KAMDAR MK, Smith SM
     Extranodal Marginal Zone Lymphoma: No Longer Just a Sidekick.
     J Clin Oncol. 2017 Apr 27:JCO2017722835. doi: 10.1200/JCO.2017.72.2835.
     PubMed     Abstract available
     
     
     
149. ZHONG WZ, Liu SY, Wu YL
     Numbers or Stations: From Systematic Sampling to Individualized Lymph Node Dissection in Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2017;35:1143-1145.
     PubMed    
     
     
     
150. PAGLIARO LC
     Role of High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Men With Previously Treated Germ Cell Tumors.
     J Clin Oncol. 2017;35:1036-1040.
     PubMed     Abstract available
     
     
     March 2017
151. TAYLOR C, Correa C, Duane FK, Aznar MC, et al
     Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.
     J Clin Oncol. 2017 Mar 20:JCO2016720722. doi: 10.1200/JCO.2016.72.0722.
     PubMed     Abstract available
     
     
     
152. SUD A, Thomsen H, Sundquist K, Houlston RS, et al
     Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History.
     J Clin Oncol. 2017 Mar 13:JCO2016709709. doi: 10.1200/JCO.2016.70.9709.
     PubMed     Abstract available
     
     
     
153. TEMEL JS, Greer JA, El-Jawahri A, Pirl WF, et al
     Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial.
     J Clin Oncol. 2017;35:834-841.
     PubMed     Abstract available
     
     
     February 2017
154. SPIGEL DR, Edelman MJ, O'Byrne K, Paz-Ares L, et al
     Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
     J Clin Oncol. 2017;35:412-420.
     PubMed     Abstract available
     
     
     December 2016
155. NAGTEGAAL ID, Knijn N, Hugen N, Marshall HC, et al
     Tumor Deposits in Colorectal Cancer: Improving the Value of Modern Staging-A Systematic Review and Meta-Analysis.
     J Clin Oncol. 2016 Dec 28:JCO2016689091.
     PubMed     Abstract available
     
     
     
156. WARDAK Z, Choy H
     Improving Treatment Options for Brain Metastases From ALK-Positive Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2016;34:4064-4065.
     PubMed    
     
     
     March 2016
157. HALABI S, Kelly WK, Ma H, Zhou H, et al
     Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
     J Clin Oncol. 2016 Mar 7. pii: JCO657270.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: